Secondary Antibody Blocking
Secondary Antibody Blocking - Related Videos
13:21
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
0 Views •
Cited by 6 •
2012
In this study, we describe an improved protocol for a multiplexed high-throughput antibody microarray with lectin detection method that can be used in glycosylation profiling of specific proteins. This protocol features new reliable reagents and significantly reduces the time, cost, and lab equipment requirements as compared to the previous procedure.
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
0 Views •
Cited by 2 •
2020
We developed a simple flow cytometry assay for evaluating the binding of PD-1–blocking antibodies to T cells, requiring only a drop of peripheral blood from cancer patients.
10:13
Method for Whole Mount Antibody Staining in Chick
0 Views •
Cited by 3 •
2009
This video demonstrates whole mount immunohistochemistry, a method by which the spatial and temporal expression pattern of an antigen can be visualized in young chick embryos. This method was originally introduced by Jane Dodd and Tom Jessell.
01:11
Secondary Healthcare System
0 Views •
2023
Secondary healthcare is offered by a specialist, generally in hospitals or clinics for patients referred by primary healthcare providers. It occurs when a person has an illness or injury that requires specific medical care. Secondary care is often referred to as acute care. Secondary care can range from uncomplicated care to repair a minor laceration or treat a strep throat infection to more complicated emergent care, such as treating a head injury sustained in an automobile accident. Whatever...
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
0 Views •
Cited by 33 •
2015
A method is described with visual accompaniment for conducting scalable, high throughput selections from phage-displayed combinatorial synthetic antibody libraries against hundreds of antigens simultaneously. Using this parallel approach, we have isolated antibody fragments that exhibit high affinity and specificity for diverse antigens that are functional in standard immunoassays.
FAQs
The blocking solution occupies reactive tissue surfaces before the labeled secondary antibody is introduced. By doing so, it can reduce secondary-antibody interactions with endogenous immunoglobulins, Fc receptors, and other sites that generate nonspecific staining. This selective reduction helps preserve antibody binding patterns that more closely represent the intended molecular targets in the sample.
Higher signal-to-background contrast makes genuine labeling easier to distinguish from diffuse or misplaced staining. In microscopy, this improves interpretation of where a neuronal protein, neurotransmitter-related marker, or cellular structure is located. Without adequate reduction of background-producing interactions, fluorescence or chromogenic signals may become difficult to assign confidently to the intended tissue feature.
The relevant sources can include reactive tissue surfaces, endogenous immunoglobulins, Fc receptors, and other background-producing sites. Because these components may contribute differently to staining artifacts, the blocking step is designed to address more than one potential interaction before secondary-antibody application. Its purpose is therefore tied to the tissue’s background sources as well as the detection assay.
Blocking prepares the tissue for detection, whereas the labeled secondary antibody provides the fluorescence or chromogenic readout. The two steps therefore have different roles: blocking reduces unwanted interactions, and the secondary antibody reveals the immunostaining pattern. Keeping this distinction clear helps researchers interpret improved specificity as a preparation benefit rather than as a separate detection signal.
A typical sequence begins by exposing the tissue to a blocking solution before the labeled secondary antibody is applied. The blocking period addresses reactive surfaces and potential interactions with endogenous immunoglobulins or Fc receptors, after which secondary-antibody labeling can be performed. This order is important because the tissue must be prepared before the detection reagent encounters it.
The central materials are a blocking solution and the labeled secondary antibody used for detection. Blocking solutions often contain proteins or other reagents selected to occupy reactive tissue sites, while the secondary antibody produces a fluorescence or chromogenic signal. Together, these components support tissue-based immunostaining that can later be examined by microscopy.
It is useful when brain or spinal cord samples are being examined for neuronal proteins, neurotransmitter-related markers, or cellular structures. Reducing nonspecific secondary-antibody binding can make molecular localization easier to interpret in neural tissue. The resulting improvement in contrast supports microscopy-based comparisons between intended staining patterns and background artifacts.
Researchers should assess whether the resulting fluorescence or chromogenic staining shows stronger specificity and clearer signal-to-background contrast. A useful outcome is improved separation between true molecular localization and background-producing artifacts. In neuroscience samples, that distinction affects how confidently investigators interpret labeling of neuronal markers, neurotransmitter-related targets, and cellular structures.